Phase 2 ready oncology drug receives FDA Orphan Drug Designation (GlobeNewswire) - Sep 17, 2018 - "Cytori Therapeutics...announced that it received FDA orphan drug designation for its ATI-1123 chemotherapy drug product candidate, an albumin-stabilized pegylated liposomal docetaxel, for the treatment of small cell lung cancer."
Orphan drug • Lung Cancer • Oncology • Small Cell Lung Cancer • Solid Tumor • Thoracic Cancer
|